Application of innate immune molecules for a new class of drugs: Infection, inflammation and beyond

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 68-75

  Kimura, H J ^a   Suzuki, K ^b   Landek Salgado, M A ^a   Caturegli, P ^a   Jounai, N ^c   Kobiyama, K ^c   Takeshita, F ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant; dsDNA; Innate immunity; Thyroid; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; BCG VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED RNA; HELICASE; IMIQUIMOD; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MINOCYCLINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; QS 21; RETINOIC ACID INDUCIBLE PROTEIN I; SM 360320; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY TITER; AUTOPHAGY; BCG VACCINATION; CANCER IMMUNIZATION; CONDYLOMA ACUMINATUM; ENCEPHALITIS; ENDOCRINE DISEASE; ENZYME INHIBITION; HASHIMOTO DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PREVENTIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA IN SITU;

EID: 79952998026     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153011794982077     Document Type: Review

References (94)

1. Rock, F.L.; Hardiman, G.; Timans, J.C.; Kastelein, R.A. and Bazan, J.F. (1998) A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA, 95, 588-593.
2. Levine, B. and Deretic, V. (2007) Unveiling the roles of autophagy in innate and adaptive immunity. Nat. Rev. Immunol., 7, 767-777.
3. Kloetzel, P.M. and Ossendorp, F. (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol., 16, 76-81.
4. Lahiri, A.; Das, P. and Chakravortty, D. (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine, 26, 6777-6783.
5. Panter, G.; Kuznik, A. and Jerala, R. (2009) Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther., 11, 133-145.
6. Ulevitch, R.J. (2004) Therapeutics targeting the innate immune system. Nat. Rev. Immunol., 4, 512-520.
7. Wong, J.P.; Christopher, M.E.; Salazar, A.M.; Dale, R.M.; Sun, L.Q. and Wang, M. (2007) Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine, 25, 3175-3178.
8. Stahl-Hennig, C.; Eisenblatter, M.; Jasny, E.; Rzehak, T.; Tenner-Racz, K.; Trumpfheller, C.; Salazar, A.M.; Uberla, K.; Nieto, K.; Kleinschmidt, J.; Schulte, R.; Gissmann, L.; Muller, M.; Sacher, A.; Racz, P.; Steinman, R.M.; Uguccioni, M. and Ignatius, R. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog., 5, e1000373.
9. Diaz, M.L. (2008) Human papilloma virus: prevention and treatment. Obstet Gynecol Clin. North. Am., 35, 199-217, vii-viii.
10. Chan, J.K. and Berek, J.S. (2007) Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol., 25, 2975-2982.
11. Lingnau, K.; Riedl, K. and von Gabain, A. (2007) IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev. Vaccines, 6, 741-746.
12. Gowen, B.B.; Fairman, J.; Dow, S.; Troyer, R.; Wong, M.H.; Jung, K.H.; Melby, P.C. and Morrey, J.D. (2009) Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res., 81, 37-46.
13. Bernstein, D.I.; Cardin, R.D.; Bravo, F.J.; Strasser, J.E.; Farley, N.; Chalk, C.; Lay, M. and Fairman, J. (2009) Potent Adjuvant Activity of Cationic Lipid-DNA Complexes for Genital Herpes Vaccines. Clin. Vaccine Immunol., 16(5), 699-705.
14. Novak, N.; Yu, C.F.; Bussmann, C.; Maintz, L.; Peng, W.M.; Hart, J.; Hagemann, T.; Diaz-Lacava, A.; Baurecht, H.J.; Klopp, N.; Wagenpfeil, S.; Behrendt, H.; Bieber, T.; Ring, J.; Illig, T. and Weidinger, S. (2007) Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy, 62, 766-772.
15. Tversky, J.R.; Le, T.V.; Bieneman, A.P.; Chichester, K.L.; Hamilton, R.G. and Schroeder, J.T. (2008) Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin. Exp. Allergy, 38, 781-788.
16. Hoffmann, P.; Wiesmuller, K.H.; Metzger, J.; Jung, G. and Bessler, W.G. (1989) Induction of tumor cytotoxicity in murine bone marrow-derived macrophages by two synthetic lipopeptide analogues. Biol. Chem. Hoppe. Seyler., 370, 575-582.
17. Bessler, W.G.; Mittenbuhler, K.; Esche, U. and Huber, M. (2003) Lipopeptide adjuvants in combination treatment. Int. Immunopharmacol., 3, 1217-1224.
18. Ingale, S.; Wolfert, M.A.; Gaekwad, J.; Buskas, T. and Boons, G.J. (2007) Robust immune responses elicited by a fully synthetic threecomponent vaccine. Nat. Chem. Biol., 3, 663-667.
19. Ingale, S.; Wolfert, M.A.; Buskas, T. and Boons, G.J. (2009) Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chem. Bio. Chem., 10, 455-463.
20. Lau, Y.F.; Deliyannis, G.; Zeng, W.; Mansell, A.; Jackson, D.C. and Brown, L.E. (2006) Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol., 18, 1801-1813.
21. Quigley, M.; Martinez, J.; Huang, X. and Yang, Y. (2009) A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood, 113, 2256-2264.
22. Alving, C.R. (1993) Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology, 187, 430-446.
23. Livingston, P.O.; Jones, M.; Deleo, A.B.; Oettgen, H.F. and Old, L.J. (1985) The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. J. Immunol., 135, 1505-1509.
24. Masihi, K.N.; Lange, W.; Brehmer, W. and Ribi, E. (1986) Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int. J. Immunopharmacol., 8, 339-345.
25. Kaufmann, S.H.; Vath, U.; Thole, J.E.; Van Embden, J.D. and Emmrich, F. (1987) Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein. Eur. J. Immunol., 17, 351-357.
26. Vernacchio, L.; Bernstein, H.; Pelton, S.; Allen, C.; MacDonald, K.; Dunn, J.; Duncan, D.D.; Tsao, G.; LaPosta, V.; Eldridge, J.; Laussucq, S.; Ambrosino, D.M. and Molrine, D.C. (2002) Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine, 20, 3658-3667.
27. Garcon, N.; Chomez, P. and Van Mechelen, M. (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines, 6, 723-739.
28. Verstraeten, T.; Descamps, D.; David, M.P.; Zahaf, T.; Hardt, K.; Izurieta, P.; Dubin, G. and Breuer, T. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine, 26, 6630-6638.
29. Ishizaka, S.T. and Hawkins, L.D. (2007) E6020: a synthetic Tolllike receptor 4 agonist as a vaccine adjuvant. Expert. Rev. Vaccines, 6, 773-784.
30. Baudner, B.C.; Ronconi, V.; Casini, D.; Tortoli, M.; Kazzaz, J.; Singh, M.; Hawkins, L.D.; Wack, A. and O'Hagan, D.T. (2009) MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020). Pharm. Res., 26, 1477-1485.
31. Zhu, Q.; Egelston, C.; Vivekanandhan, A.; Uematsu, S.; Akira, S.; Klinman, D.M.; Belyakov, I.M. and Berzofsky, J.A. (2008) Tolllike receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. USA, 105, 16260-16265.
32. Zhang, W.W. and Matlashewski, G. (2008) Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun., 76, 3777-3783.
33. Adams, S.; O'Neill, D.W.; Nonaka, D.; Hardin, E.; Chiriboga, L.; Siu, K.; Cruz, C.M.; Angiulli, A.; Angiulli, F.; Ritter, E.; Holman, R.M.; Shapiro, R.L.; Berman, R.S.; Berner, N.; Shao, Y.; Manches, O.; Pan, L.; Venhaus, R.R.; Hoffman, E.W.; Jungbluth, A.; Gnjatic, S.; Old, L.; Pavlick, A.C. and Bhardwaj, N. (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol., 181, 776-784.
34. Dharmapuri, S.; Aurisicchio, L.; Neuner, P.; Verdirame, M.; Ciliberto, G. and La Monica, N. (2009) An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer. Gene. Ther., 16, 462-472.
35. Hayashi, T.; Gray, C.S.; Chan, M.; Tawatao, R.I.; Ronacher, L.; McGargill, M.A.; Datta, S.K.; Carson, D.A. and Corr, M. (2009) Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc. Natl. Acad. Sci. USA, 106, 2764-2769.
36. Kanneganti, T.D.; Lamkanfi, M. and Nunez, G. (2007) Intracellular NOD-like receptors in host defense and disease. Immunity., 27, 549-559.
37. Coulombe, F.; Divangahi, M.; Veyrier, F.; de Leseleuc, L.; Gleason, J.L.; Yang, Y.; Kelliher, M.A.; Pandey, A.K.; Sassetti, C.M.; Reed, M.B. and Behr, M.A. (2009) Increased NOD2- mediated recognition of N-glycolyl muramyl dipeptide. J. Exp. Med., 206, 1709-1716.
38. Meshcheryakova, E.; Makarov, E.; Philpott, D.; Andronova, T. and Ivanov, V. (2007) Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-Nacetylmuramyl peptides. Vaccine, 25, 4515-4520.
39. Watanabe, T.; Asano, N.; Murray, P.J.; Ozato, K.; Tailor, P.; Fuss, I.J.; Kitani, A. and Strober, W. (2008) Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest., 118, 545-559.
40. Bertrand, M.J.; Doiron, K.; Labbe, K.; Korneluk, R.G.; Barker, P.A. and Saleh, M. (2009) Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity, 30, 789-801.
41. Yokota, Y.; Watanabe, Y.; Wakai, Y. and Mine, Y. (1992) Protective effects of immunoactive peptide, FK565 against systemic and local infections with herpes simplex virus and murine cytomegalovirus and respiratory tract infection with influenza virus in mice. J. Antibiot. (Tokyo), 45, 258-264.
42. Sato, Y.; Maruyama, S.; Kawai, C. and Matsumori, A. (1992) Effect of immunostimulant therapy on acute viral myocarditis in an animal model. Am. Heart. J., 124, 428-434.
43. Cassel, S.L.; Joly, S. and Sutterwala, F.S. (2009) The NLRP3 inflammasome: a sensor of immune danger signals. Semin. Immunol., 21, 194-198.
44. De Gregorio, E.; D'Oro, U. and Wack, A. (2009) Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol., 21, 339-345.
45. Hiscott, J.; Lin, R.; Nakhaei, P. and Paz, S. (2006) MasterCARD: a priceless link to innate immunity. Trends. Mol. Med., 12, 53-56.
46. Kobiyama, K.; Takeshita, F.; Ishii, K.J.; Koyama, S.; Aoshi, T.; Akira, S.; Sakaue-Sawano, A.; Miyawaki, A.; Yamanaka, Y.; Hirano, H.; Suzuki, K. and Okuda, K. (2009) A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J. Immunol., 182, 1593-1601.
47. Werninghaus, K.; Babiak, A.; Gross, O.; Holscher, C.; Dietrich, H.; Agger, E.M.; Mages, J.; Mocsai, A.; Schoenen, H.; Finger, K.; Nimmerjahn, F.; Brown, G.D.; Kirschning, C.; Heit, A.; Andersen, P.; Wagner, H.; Ruland, J. and Lang, R. (2009) Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J. Exp. Med., 206, 89-97.
48. Breckpot, K.; Aerts-Toegaert, C.; Heirman, C.; Peeters, U.; Beyaert, R.; Aerts, J.L. and Thielemans, K. (2009) Attenuated expression of A20 markedly increases the efficacy of doublestranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol., 182, 860-870.
49. Barrat, F.J. and Coffman, R.L. (2008) Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev., 223, 271-283.
50. Gearing, A.J. (2007) Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell. Biol., 85, 490-494.
51. Chang, Y.C.; Kao, W.C.; Wang, W.Y.; Wang, W.Y.; Yang, R.B. and Peck, K. (2009) Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J., 23, 3078-3088.
52. Sacre, S.M.; Lo, A.; Gregory, B.; Simmonds, R.E.; Williams, L.; Feldmann, M.; Brennan, F.M. and Foxwell, B.M. (2008) Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J. Immunol., 181, 8002-8009.
53. Bowie, A.; Kiss-Toth, E.; Symons, J.A.; Smith, G.L.; Dower, S.K. and O'Neill, L.A. (2000) A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. USA, 97, 10162-10167.
54. Li, K.; Foy, E.; Ferreon, J.C.; Nakamura, M.; Ferreon, A.C.; Ikeda, M.; Ray, S.C.; Gale, M.Jr. and Lemon, S.M. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA, 102, 2992-2997.
55. Li, X.D.; Sun, L.; Seth, R.B.; Pineda, G. and Chen, Z.J. (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA, 102, 17717-17722.
56. Stack, J.; Haga, I.R.; Schroder, M.; Bartlett, N.W.; Maloney, G.; Reading, P.C.; Fitzgerald, K.A.; Smith, G.L. and Bowie, A.G. (2005) Vaccinia virus protein A46R targets multiple Toll-likeinterleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med., 201, 1007-1018.
57. Levine, B. and Kroemer, G. (2008) Autophagy in the pathogenesis of disease. Cell, 132, 27-42.
58. Jagannath, C.; Lindsey, D.R.; Dhandayuthapani, S.; Xu, Y.; Hunter, R.L.Jr. and Eissa, N.T. (2009) Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med., 15, 267-276.
59. Jounai, N.; Takeshita, F.; Kobiyama, K.; Sawano, A.; Miyawaki, A.; Xin, K.Q.; Ishii, K.J.; Kawai, T.; Akira, S.; Suzuki, K. and Okuda, K. (2007) The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl. Acad. Sci. USA, 104, 14050-14055.
60. Saitoh, T.; Fujita, N.; Jang, M.H.; Uematsu, S.; Yang, B.G.; Satoh, T.; Omori, H.; Noda, T.; Yamamoto, N.; Komatsu, M.; Tanaka, K.; Kawai, T.; Tsujimura, T.; Takeuchi, O.; Yoshimori, T. and Akira, S. (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature, 456, 264-268.
61. Tanaka, K. (2009) The proteasome: overview of structure and functions. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci., 85, 12-36.
62. Muchamuel, T.; Basler, M.; Aujay, M.A.; Suzuki, E.; Kalim, K.W.; Lauer, C.; Sylvain, C.; Ring, E.R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S.D.; Bennett, M.K.; Kirk, C.J. and Groettrup, M. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med., 15, 781-787.
63. Bennett, M.K. and Kirk, C.J. (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr. Opin. Drug. Discov. Dev., 11, 616-625.
64. Neubert, K.; Meister, S.; Moser, K.; Weisel, F.; Maseda, D.; Amann, K.; Wiethe, C.; Winkler, T.H.; Kalden, J.R.; Manz, R.A. and Voll, R.E. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med., 14, 748-755.
65. Kuhn, D.J.; Hunsucker, S.A.; Chen, Q.; Voorhees, P.M.; Orlowski, M. and Orlowski, R.Z. (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 113, 4667-4676.
66. Viola, A. and Luster, A.D. (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol., 48, 171-197.
67. Renckens, R.; Roelofs, J.J.; Florquin, S.; de Vos, A.F.; Lijnen, H.R.; van't Veer, C. and van der Poll, T. (2006) Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J. Immunol., 176, 3735-3741.
68. Hu, W.; Metselaar, J.; Ben, L.H.; Cravens, P.D.; Singh, M.P.; Frohman, E.M.; Eagar, T.N.; Racke, M.K.; Kieseier, B.C. and Stuve, O. (2009) PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One, 4, e4151.
69. Gaestel, M.; Kotlyarov, A. and Kracht, M. (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug. Discov., 8, 480-499.
70. Ishii, K.J.; Suzuki, K.; Coban, C.; Takeshita, F.; Itoh, Y.; Matoba, H.; Kohn, L.D. and Klinman, D.M. (2001) Genomic DNA released by dying cells induces the maturation of APCs. J. Immunol., 167, 2602-2607.
71. Suzuki, K.; Mori, A.; Ishii, K.J.; Saito, J.; Singer, D.S.; Klinman, D.M.; Krause, P.R. and Kohn, L.D. (1999) Activation of targettissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl. Acad. Sci. USA, 96, 2285-2290.
72. Shimojo, N.; Kohno, Y.; Yamaguchi, K.; Kikuoka, S.; Hoshioka, A.; Niimi, H.; Hirai, A.; Tamura, Y.; Saito, Y.; Kohn, L.D. and Tahara, K. (1996) Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc. Natl. Acad. Sci. USA, 93, 11074-11079.
73. Costagliola, S.; Many, M.C.; Denef, J.F.; Pohlenz, J.; Refetoff, S. and Vassart, G. (2000) Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J. Clin. Invest., 105, 803-811.
74. Blechynden, L.M.; Lawson, M.A.; Tabarias, H.; Garlepp, M.J.; Sherman, J.; Raben, N. and Lawson, C.M. (1997) Myositis induced by naked DNA immunization with the gene for histidyl-tRNA synthetase. Hum. Gene Ther., 8, 1469-1480.
75. Bar-Shavit, Z. (2008) Taking a toll on the bones: regulation of bone metabolism by innate immune regulators. Autoimmunity, 41, 195-203.
76. Takayanagi, H. (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol., 7, 292-304.
77. Shi, H.; Kokoeva, M.V.; Inouye, K.; Tzameli, I.; Yin, H. and Flier, J.S. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest., 116, 3015-3025.
78. Davis, J.E.; Gabler, N.K.; Walker-Daniels, J. and Spurlock, M.E. (2008) Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring), 16, 1248-1255.
79. Tsukumo, D.M.; Carvalho-Filho, M.A.; Carvalheira, J.B.; Prada, P.O.; Hirabara, S.M.; Schenka, A.A.; Araujo, E.P.; Vassallo, J.; Curi, R.; Velloso, L.A. and Saad, M.J. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes, 56, 1986-1998.
80. Cousin, B.; Munoz, O.; Andre, M.; Fontanilles, A.M.; Dani, C.; Cousin, J.L.; Laharrague, P.; Casteilla, L. and Penicaud, L. (1999) A role for preadipocytes as macrophage-like cells. FASEB J., 13, 305-312.
81. Charriere, G.; Cousin, B.; Arnaud, E.; Andre, M.; Bacou, F.; Penicaud, L. and Casteilla, L. (2003) Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem., 278, 9850-9855.
82. Pietsch, J.; Batra, A.; Stroh, T.; Fedke, I.; Glauben, R.; Okur, B.; Zeitz, M. and Siegmund, B. (2006) Toll-like receptor expression and response to specific stimulation in adipocytes and preadipocytes: on the role of fat in inflammation. Ann. NY Acad. Sci., 1072, 407-409.
83. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L. and Ferrante, A.W.Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 1796-1808.
84. Ehses, J.A.; Perren, A.; Eppler, E.; Ribaux, P.; Pospisilik, J.A.; Maor-Cahn, R.; Gueripel, X.; Ellingsgaard, H.; Schneider, M.K.; Biollaz, G.; Fontana, A.; Reinecke, M.; Homo-Delarche, F. and Donath, M.Y. (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes, 56, 2356-2370.
85. Kopp, A.; Buechler, C.; Neumeier, M.; Weigert, J.; Aslanidis, C.; Scholmerich, J. and Schaffler, A. (2009) Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring), 17, 648-656.
86. Duffaut, C.; Galitzky, J.; Lafontan, M. and Bouloumie, A. (2009) Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem. Biophys. Res. Commun., 384, 482-485.
87. Nijhuis, J.; Rensen, S.S.; Slaats, Y.; van Dielen, F.M.; Buurman, W.A. and Greve, J.W. (2009) Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring), 17(11), 2014-2018
88. Rocchi, R.; Kimura, H.; Tzou, S.C.; Suzuki, K.; Rose, N.R.; Pinchera, A.; Ladenson, P.W. and Caturegli, P. (2007) Toll-like receptor-MyD88 and Fc receptor pathways of mast cells mediate the thyroid dysfunctions observed during nonthyroidal illness. Proc. Natl. Acad. Sci. USA, 104, 6019-6024.
89. Bornstein, S.R.; Zacharowski, P.; Schumann, R.R.; Barthel, A.; Tran, N.; Papewalis, C.; Rettori, V.; McCann, S.M.; Schulze-Osthoff, K.; Scherbaum, W.A.; Tarnow, J. and Zacharowski, K. (2004) Impaired adrenal stress response in Toll-like receptor 2- deficient mice. Proc. Natl. Acad. Sci. USA, 101, 16695-16700.
90. Yamazaki, K.; Suzuki, K.; Yamada, E.; Yamada, T.; Takeshita, F.; Matsumoto, M.; Mitsuhashi, T.; Obara, T.; Takano, K. and Sato, K. (2007) Suppression of iodide uptake and thyroid hormone synthesis with stimulation of the type I interferon system by double-stranded ribonucleic acid in cultured human thyroid follicles. Endocrinology, 148, 3226-3235.
91. Harii, N.; Lewis, C.J.; Vasko, V.; McCall, K.; Benavides-Peralta, U.; Sun, X.; Ringel, M.D.; Saji, M.; Giuliani, C.; Napolitano, G.; Goetz, D.J. and Kohn, L.D. (2005) Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Mol. Endocrinol., 19, 1231-1250.
92. Huang, J. and Klionsky, D.J. (2007) Autophagy and human disease. Cell Cycle, 6, 1837-1849.
93. Singh, R.; Kaushik, S.; Wang, Y.; Xiang, Y.; Novak, I.; Komatsu, M.; Tanaka, K.; Cuervo, A.M. and Czaja, M.J. (2009) Autophagy regulates lipid metabolism. Nature, 458, 1131-1135.
94. Moro, J.R.; Iwata, M. and von Andriano, U.H. (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol., 8, 685-698.